Tarsus Pharmaceuticals posts 69% sales jump, raises 2026 guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Tarsus Pharmaceuticals posts 69% sales jump, raises 2026 guidance

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

August 6, 2026 7:03 AM EDT

Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year

Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million

Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus retina pipeline with a Phase 3 clinical program for Stargardt disease, an inherited retinal disease affecting more than 36,000 patients in the United States that can lead to blindness

Priced $125 million private placement financing which included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors 

... More